Company Description
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space.
The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter.
The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system.
Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
| Country | United States |
| Founded | 2010 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Harel Gadot |
Contact Details
Address: 288 Grove Street , Suite 388 Braintree, Massachusetts 02184 United States | |
| Phone | 781 875 3605 |
| Website | microbotmedical.com |
Stock Details
| Ticker Symbol | MBOT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000883975 |
| CUSIP Number | 59503A204 |
| ISIN Number | US59503A2042 |
| Employer ID | 94-3078125 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Harel Gadot | Co-Founder, President, Chief Executive Officer and Chairman |
| Yoseph Bornstein | Co-Founder and Independent Director |
| Rachel Vaknin | Chief Financial Officer |
| Dr. Simon Sharon MBA, MSc | Chief Technology Officer and GM of Microbot Israel |
| Dr. Juan Diaz-Cartelle | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 6, 2024 | ARS | Filing |
| Nov 6, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 15, 2024 | 424B3 | Prospectus |
| Oct 15, 2024 | 424B3 | Prospectus |
| Oct 15, 2024 | 8-K | Current Report |
| Oct 11, 2024 | 8-K | Current Report |
| Oct 1, 2024 | 424B3 | Prospectus |